BioNTech SE (NASDAQ:BNTX) ranks among the best high growth European stocks to buy. On January 16, Goldman Sachs upgraded ...

Company expands its ADC pipeline and patent estate for novel, differentiated ADCsNew pipeline candidate AKTX-102 leverages ...

Akari Therapeutics has filed a new US provisional patent covering AKTX-102, its second antibody drug conjugate targeting ...

Three-program alliance with Synaffix reflects SOTIO’s commitment to further broaden and advance innovative ADC pipeline PRAGUE & AMSTERDAM--(BUSINESS WIRE)-- SOTIO Biotech, a clinical-stage ...

-- Following recently signed global license agreement with Synaffix, EO-1022 leverages the company's GlycoConnect® and HydraSpace® ADC technologies for glycan site-specific conjugation and SYNstatin ...

Ellipses Pharma Limited (“Ellipses”), a clinical-stage oncology drug development company with a pipeline of innovative ...

SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug ...

USD 361 million round represents the largest Series C for a European biotechnology company and the largest financing for a private ADC developer globally Round led by Venrock Healthcare Capital ...

The series A investment round secures resources for advancing global Phase I/II clinical programs and orchestrating the company's global footprint expansion. BEIJING, Nov. 28, 2024 /PRNewswire/ -- ...

Financing led by TCGX, including new investment from TPG, Orbimed Advisors, Venrock Healthcare Capital Partners, Surveyor Capital (a Citadel company), and Logos Capital, with participation from all ...

Stephens analyst has initiated coverage on ADC Therapeutics SA (NYSE:ADCT), a commercial-stage oncology-focused biotechnology company developing antibody-drug conjugates (ADCs) for patients with ...

PRAGUE & AMSTERDAM--(BUSINESS WIRE)--SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced it will be exercising its option, under its license and option ...